Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186418 · ClinicalTrials.gov registry record · Phase 1
Gene Transfer for Patients With Sickle Cell Disease
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02186418 is a Phase 1 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 7 participants.
The verdict
NCT02186418, a Phase 1 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease
Interventions
- GENETIC ARU-1801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-07 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02186418
The ClinicalTrials.gov registry entry for NCT02186418 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARU-1801 is the first listed.
NCT02186418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02186418 about?
NCT02186418 is a clinical study titled "Gene Transfer for Patients With Sickle Cell Disease". The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease
What is the current status of trial NCT02186418?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2014-07. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT02186418?
The interventions under investigation include: ARU-1801 (GENETIC).
Who is sponsoring clinical trial NCT02186418?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.